Jupiter Neurosciences, Inc. - JUNS Enterprise Value-to-Revenue Multiple

Jupiter Neurosciences Inc (JUNS) - corporate logo

Jupiter Neurosciences Inc (JUNS) is developing an advanced platform to combat brain inflammation by overcoming neuronal barriers. The business outlook depends on the bioavailability of JNS101 and the efficacy of resveratrol in treating Alzheimer's disease. The Enterprise Value to revenue ratio visualizes the asset's market value, with the latest value recorded as 26000.00. Long-term drivers are linked to the publication of test data, while R&D risks are already priced in.

JUNS Jupiter Neurosciences, Inc. Enterprise Value-to-Revenue Ratio (11/23/2025 - 11/20/2026)

JUNS (jupiterneurosciences.com): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Fundamental company valuation:Jupiter Neurosciences Inc
Core merchandise of Jupiter Neurosciences Inc

For Jupiter Neurosciences Inc (JUNS), which utilizes outsourcing for production and marketing, the EV/Revenue ratio on the GURU.Markets platform reflects the market value of the business excluding debt load. This indicator compares the total enterprise value with sales volume, allowing investors to assess the efficiency of revenue capitalization and the resilience of assets to market shocks regardless of credit policy.

Competitor analysis for Jupiter Neurosciences Inc

BIIB (Biogen Inc.) - Company Value to Revenue Ratio|NBIX: EV/Sales Multiple|RGC (Regencell Bioscience Holdings Limited) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Axsome Therapeutics Inc|ACAD: Business Value to Revenue|EV/Sales Multiple XENE|EV/Sales Multiple vikingtherapeutics.com (VKTX)|Enterprise Value-to-Revenue Ratio Supernus SUPN|Business Value to Revenue CPRX|denalitherapeutics.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Harmony Pharma HRMY|BHVN: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Amylyx Pharmaceuticals, Inc. (AMLX)|TRVI (Trevi Therapeutics Inc) - EV/Sales Multiple|Company Value to Revenue Ratio PRAX (Praxis Medicines)|Enterprise Value-to-Revenue Ratio Anavex Life Sciences (AVXL)|Enterprise Value-to-Revenue Ratio CBLL (CeriBell EEG)|EV/Sales Multiple PRTA (Prothena Corp)|alector.com (ALEC) - Enterprise Value-to-Revenue Multiple|ANNX: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Omeros|NGNE: EV/Sales Multiple|Company Value to Revenue AC Immune|Company Value to Revenue VYGR|Company Value to Revenue Ratio NMRA (neumoratx.com)|Company Value to Revenue SCLX (Scilex Holding Company, Inc.)|Enterprise Value-to-Revenue Ratio TVGN (Tevogen Bio)|Enterprise Value-to-Revenue Ratio Alpha Cognition ACOG|CGTX - Company Value to Revenue|IKT - Enterprise Value-to-Revenue Ratio|SAVA: Enterprise Value-to-Revenue Ratio|Assertio Therapeutics (ASRT) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Coya Therapeutics Inc (COYA)|Enterprise Value-to-Revenue Ratio Vistagen|Company Value to Revenue Ratio OVID (ovidrx.com)|Enterprise Value-to-Revenue Ratio Acumen Pharmaceuticals, Inc. (ABOS)|CRVO - Enterprise Value-to-Revenue Multiple|Alterity Therapeutics Ltd. - Company Value to Revenue|CLNN - Company Value to Revenue|PEPG - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Relmada Corp|ANVS (Annovis Bio, Inc.) - Company Value to Revenue|Grace Tx (GRCE) - EV/Sales Multiple|Company Value to Revenue AIFF|EV/Sales Multiple anewmeds.com|Enterprise Value-to-Revenue Ratio NeuroSense Therapeutics (NRSN)|RVPH (Reviva Pharmaceuticals Holdings) - Business Value to Revenue|MetaVia - Company Value to Revenue|NRXS: Company Value to Revenue Ratio|Helius Medical Technologies, Inc. - EV/Sales Multiple|PASG: Enterprise Value-to-Revenue Ratio|Neuphoria (NEUP) - Enterprise Value-to-Revenue Ratio|Minerva Neurosciences - Business Value to Revenue|ATHA (Athira Pharma, Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple addextherapeutics.com ADXN|Company Value to Revenue ALZN (Alzamend Neuro Inc.)|CYCN (Cyclerion Therapeutics, Inc.) - Business Value to Revenue|EV/Sales Multiple PTIX (Protagenic)|EV/Sales Multiple pasitheaclinics.com KTTA|CRGT - Enterprise Value-to-Revenue Ratio|Business Value to Revenue ATXI (Avenue Therapeutics)|BCLI: EV/Sales Multiple|Cara Therapeutics - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Chromocell Therapeutics Corporation|EV/Sales Multiple Eliem Therapeutics Inc.|Enterprise Value-to-Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|LBPH (Longboard Pharmaceuticals) - Business Value to Revenue|EV/Sales Multiple MRNS (marinuspharma.com)|NKGN: Company Value to Revenue Ratio|NRBO - Enterprise Value-to-Revenue Ratio|SAGE - EV/Sales Multiple|Synaptogenix (SNPX) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Trevena (TRVN)|Company Value to Revenue VIGL|Company Value to Revenue Ratio WENA (Anew Medical)|EV/Sales Multiple CERE